A new publication referencing difelikefalin appeared on June 12, 2026. The article, titled "Pharmacology of pruritus (pathophysiology, therapeutic targets)," was published in the journal Therapie. The publication addresses the pathophysiology of pruritus and discusses therapeutic targets relevant to the condition. Difelikefalin, an approved compound, is included within the scope of this review.
The publication is indexed under PubMed ID 42362454 and is available through the journal's listing. As a publication-type event, this entry reflects the appearance of new literature rather than new trial results or safety findings. No specific findings, conclusions, or data points beyond the publication's title and journal placement have been provided.
Readers interested in the pharmacological context of pruritus treatment approaches may find this publication relevant to ongoing discussions in the field. This brief reports only the fact of the publication's appearance in Therapie on the stated date, without characterizing its content further.
For more background on difelikefalin, including its approved status and general information, readers can consult the compound overview.